Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE EXTENSION: Long-term Safety and Efficacy of Ralinepag in PAH
NCT03683186Phase 3Enrolling by invitation
- Sponsor
- United Therapeutics Corporation
- Start
- Sep 2019
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 33
01
Overview
A Phase 3 trial of ralinepag in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Started Sep 2019; status: enrolling by invitation.
02
Drugs
ralinepag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03683186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03683186.